Search

Your search keyword '"Matsuo, K"' showing total 723 results
Start Over Author "Matsuo, K" Publication Year Range Last 3 years
723 results on '"Matsuo, K"'

2. Using a Systems Engineering Approach to Build a PCR Testing System at a Medical School During the COVID-19 Pandemic

Author

Oba J, Toriya M, Uwamino Y, and Matsuo K

Subjects
covid-19, pcr test, clinical laboratory, systems engineering, diagram, temporary system, Public aspects of medicine, RA1-1270
Abstract

Junna Oba,1 Masako Toriya,2 Yoshifumi Uwamino,3 Koichi Matsuo4 1Department of Extended Intelligence for Medicine, the Ishii-Ishibashi Laboratory, Keio University School of Medicine, Tokyo, Japan; 2Global Research Institute, Keio University, Tokyo, Japan; 3Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan; 4Collaborative Research Resources, Keio University School of Medicine, Tokyo, JapanCorrespondence: Masako Toriya, Global Research Institute, Keio University, 2-15-45 Mita, Minato-ku, Tokyo, 108-8345, Japan, Tel +81-3-5427-1379, Fax +81-3-5427-1703, Email masako.toriya@keio.jpBackground: During the COVID-19 pandemic, there was an increasing need to expand diagnostic testing in hospitals. At Keio University Hospital (KUH), clinical staff were concerned that the demand for PCR testing might exceed the capacity of the Clinical Laboratory. In response, basic researchers at Keio University School of Medicine (KUSM) set out to build a new, collaborative, PCR testing system. To be authorized to perform such diagnostic PCR testing, KUSM registered its core laboratory as an external clinical laboratory (ECL).Methods: In the pandemic, there was a pressure to build the PCR system quickly. Speed required discussions that developed a shared understanding of the unprecedented, new KUH/KUSM PCR system. To design, construct, and archive the new PCR testing system, we used a systems engineering (SE) approach. This included diagram visualization of functional flows and application of the Unified Architecture Framework (UAF), both of which are often used in system building. We considered daily demand for PCR testing at KUH and KUSM, and daily COVID-19 infections in Japan.Results: We operated the collaborative PCR testing system from August 2020 to June 2022. Given public health insurance reimbursement policies, KUH focused on individuals with suspicious symptoms, while the ECL at KUSM screened samples from asymptomatic individuals. KUSM performed about half as many tests as KUH. Interviewing KUH staff revealed that diagrams helped promote a better understanding of the KUH/KUSM PCR testing system.Conclusion: When designing temporary systems that may be repurposed in the future, we suggest using an SE approach with diagrams and UAF perspectives. This approach will enable stakeholders to understand what is being proposed to be built, and facilitate achieving an informed consensus on the proposed system. We suggest that SE approaches should be widely used in projects that involve building and operating complex, collaborative systems, and documenting the process. Keywords: COVID-19, PCR test, clinical laboratory, systems engineering, diagram, temporary system

Published
2024

3. Long-term exposure to particulate matter and all-cause and cause-specific mortality in an analysis of multiple Asian cohorts

Author

Downward, G.S., Hystad, P., Tasmin, S., Abe, S.K., Saito, E, Rahman, M.S., Islam, M.R., Gupta, P.C., Sawada, N., Malekzadeh, R., You, S.L., Ahsan, H., Park, S.K., Pednekar, M.S., Tsugane, S., Etemadi, A., Chen, C.J., Shin, A., Chen, Y., Boffetta, P., Chia, K.S., Matsuo, K., Qiao, Y.L., Rothman, N., Zheng, W., Inoue, M., Kang, D., Lan, Q., and Vermeulen, R.C.H

Published
2024
Full Text
View/download PDF

9. Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium

Author

Goyal, N, Hennessy, M, Lehman, E, Lin, W, Agudo, A, Ahrens, W, Boccia, S, Brennan, P, Brenner, H, Cadoni, G, Canova, C, Chen, C, Conway, D, Curado, M, Dal Maso, L, Daudt, A, Edefonti, V, Fabianova, E, Fernandez, L, Franceschi, S, Garavello, W, Gillison, M, Hayes, R, Healy, C, Herrero, R, Holcatova, I, Kanda, J, Kelsey, K, Hansen, B, Koifman, R, Lagiou, P, La Vecchia, C, Levi, F, Li, G, Lissowska, J, Mendoza Lopez, R, Luce, D, Macfarlane, G, Mates, D, Matsuo, K, Mcclean, M, Menezes, A, Menvielle, G, Morgenstern, H, Moysich, K, Negri, E, Olshan, A, Pandics, T, Polesel, J, Purdue, M, Radoi, L, Ramroth, H, Richiardi, L, Schantz, S, Schwartz, S, Serraino, D, Shangina, O, Smith, E, Sturgis, E, Swiatkowska, B, Thomson, P, Vaughan, T, Vilensky, M, Winn, D, Wunsch-Filho, V, Yu, G, Zevallos, J, Zhang, Z, Zheng, T, Znaor, A, Boffetta, P, Hashibe, M, Lee, Y, Muscat, J, Goyal N., Hennessy M., Lehman E., Lin W., Agudo A., Ahrens W., Boccia S., Brennan P., Brenner H., Cadoni G., Canova C., Chen C., Conway D., Curado M., Dal Maso L., Daudt A. W., Edefonti V., Fabianova E., Fernandez L., Franceschi S., Garavello W., Gillison M., Hayes R. B., Healy C., Herrero R., Holcatova I., Kanda J. L., Kelsey K., Hansen B., Koifman R., Lagiou P., La Vecchia C., Levi F., Li G., Lissowska J., Mendoza Lopez R., Luce D., Macfarlane G., Mates D., Matsuo K., McClean M., Menezes A., Menvielle G., Morgenstern H., Moysich K., Negri E., Olshan A. F., Pandics T., Polesel J., Purdue M., Radoi L., Ramroth H., Richiardi L., Schantz S., Schwartz S. M., Serraino D., Shangina O., Smith E., Sturgis E. M., Swiatkowska B., Thomson P., Vaughan T. L., Vilensky M., Winn D. M., Wunsch-Filho V., Yu G. -P., Zevallos J. P., Zhang Z. -F., Zheng T., Znaor A., Boffetta P., Hashibe M., Lee Y. -C. A., Muscat J. E., Goyal, N, Hennessy, M, Lehman, E, Lin, W, Agudo, A, Ahrens, W, Boccia, S, Brennan, P, Brenner, H, Cadoni, G, Canova, C, Chen, C, Conway, D, Curado, M, Dal Maso, L, Daudt, A, Edefonti, V, Fabianova, E, Fernandez, L, Franceschi, S, Garavello, W, Gillison, M, Hayes, R, Healy, C, Herrero, R, Holcatova, I, Kanda, J, Kelsey, K, Hansen, B, Koifman, R, Lagiou, P, La Vecchia, C, Levi, F, Li, G, Lissowska, J, Mendoza Lopez, R, Luce, D, Macfarlane, G, Mates, D, Matsuo, K, Mcclean, M, Menezes, A, Menvielle, G, Morgenstern, H, Moysich, K, Negri, E, Olshan, A, Pandics, T, Polesel, J, Purdue, M, Radoi, L, Ramroth, H, Richiardi, L, Schantz, S, Schwartz, S, Serraino, D, Shangina, O, Smith, E, Sturgis, E, Swiatkowska, B, Thomson, P, Vaughan, T, Vilensky, M, Winn, D, Wunsch-Filho, V, Yu, G, Zevallos, J, Zhang, Z, Zheng, T, Znaor, A, Boffetta, P, Hashibe, M, Lee, Y, Muscat, J, Goyal N., Hennessy M., Lehman E., Lin W., Agudo A., Ahrens W., Boccia S., Brennan P., Brenner H., Cadoni G., Canova C., Chen C., Conway D., Curado M., Dal Maso L., Daudt A. W., Edefonti V., Fabianova E., Fernandez L., Franceschi S., Garavello W., Gillison M., Hayes R. B., Healy C., Herrero R., Holcatova I., Kanda J. L., Kelsey K., Hansen B., Koifman R., Lagiou P., La Vecchia C., Levi F., Li G., Lissowska J., Mendoza Lopez R., Luce D., Macfarlane G., Mates D., Matsuo K., McClean M., Menezes A., Menvielle G., Morgenstern H., Moysich K., Negri E., Olshan A. F., Pandics T., Polesel J., Purdue M., Radoi L., Ramroth H., Richiardi L., Schantz S., Schwartz S. M., Serraino D., Shangina O., Smith E., Sturgis E. M., Swiatkowska B., Thomson P., Vaughan T. L., Vilensky M., Winn D. M., Wunsch-Filho V., Yu G. -P., Zevallos J. P., Zhang Z. -F., Zheng T., Znaor A., Boffetta P., Hashibe M., Lee Y. -C. A., and Muscat J. E.

Abstract

Objective: We analyzed the pooled case-control data from the International Head and Neck Cancer Epidemiology (INHANCE) consortium to compare cigarette smoking and alcohol consumption risk factors for head and neck cancer between less developed and more developed countries. Subjects and Methods: The location of each study was categorized as either a less developed or more developed country. We compared the risk of overall head and neck cancer and cancer of specific anatomic subsites associated with cigarette smoking and alcohol consumption. Additionally, age and sex distribution between categories was compared. Results: The odds ratios for head and neck cancer sites associated with smoking duration differed between less developed and more developed countries. Smoking greater than 20 years conferred a higher risk for oral cavity and laryngeal cancer in more developed countries, whereas the risk was greater for oropharynx and hypopharynx cancer in less developed countries. Alcohol consumed for more than 20 years conferred a higher risk for oropharynx, hypopharynx, and larynx cancer in less developed countries. The proportion of cases that were young (<45 years) or female differed by country type for some HNC subsites. Conclusion: These findings suggest the degree of industrialization and economic development affects the relationship between smoking and alcohol with head and neck cancer.

Published
2023

20. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis.

Author

Fu, Z., Brooks, M.M., Irvin, S., Jordan, S., Aben, K.K.H., Anton-Culver, H., Bandera, E.V., Beckmann, M.W., Berchuck, A., Brooks-Wilson, A., Chang-Claude, J., Cook, L.S., Cramer, D.W, Cushing-Haugen, K.L., Doherty, J.A., Ekici, A.B., Fasching, P.A., Fortner, R.T., Gayther, S.A., Gentry-Maharaj, A., Giles, G.G., Goode, E.L., Goodman, M.T., Harris, H.R., Hein, A., Kaaks, R., Kiemeney, L.A., Köbel, M., Kotsopoulos, J., Le, N.D., Lee, A.W.C., Matsuo, K., McGuire, V., McLaughlin, J.R., Menon, U., Milne, R.L., Moysich, K.B., Pearce, C.L., Pike, M.C., Qin, B., Ramus, S.J., Riggan, M.J., Rothstein, J.H., Schildkraut, J.M., Sieh, W., Sutphen, R., Terry, K.L., Thompson, P.J., Titus, L., Altena, A.M. van, White, E., Whittemore, A.S., Wu, A.H., Zheng, W., Ziogas, Argyrios, Taylor, S.E., Tang, L., Songer, T., Wentzensen, N., Webb, P.M., Risch, H.A., Modugno, F., Fu, Z., Brooks, M.M., Irvin, S., Jordan, S., Aben, K.K.H., Anton-Culver, H., Bandera, E.V., Beckmann, M.W., Berchuck, A., Brooks-Wilson, A., Chang-Claude, J., Cook, L.S., Cramer, D.W, Cushing-Haugen, K.L., Doherty, J.A., Ekici, A.B., Fasching, P.A., Fortner, R.T., Gayther, S.A., Gentry-Maharaj, A., Giles, G.G., Goode, E.L., Goodman, M.T., Harris, H.R., Hein, A., Kaaks, R., Kiemeney, L.A., Köbel, M., Kotsopoulos, J., Le, N.D., Lee, A.W.C., Matsuo, K., McGuire, V., McLaughlin, J.R., Menon, U., Milne, R.L., Moysich, K.B., Pearce, C.L., Pike, M.C., Qin, B., Ramus, S.J., Riggan, M.J., Rothstein, J.H., Schildkraut, J.M., Sieh, W., Sutphen, R., Terry, K.L., Thompson, P.J., Titus, L., Altena, A.M. van, White, E., Whittemore, A.S., Wu, A.H., Zheng, W., Ziogas, Argyrios, Taylor, S.E., Tang, L., Songer, T., Wentzensen, N., Webb, P.M., Risch, H.A., and Modugno, F.

Abstract

Item does not contain fulltext, BACKGROUND: The role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored the association between lifetime ovulatory years (LOY) and EOC. METHODS: LOY was calculated using 12 algorithms. Odds ratios (ORs) and 95% confidence intervals (CIs) estimated the association between LOY or LOY components and EOC among 26 204 control participants and 21 267 case patients from 25 studies. To assess whether LOY components act through ovulation suppression alone, we compared beta coefficients obtained from regression models with expected estimates assuming 1 year of ovulation suppression has the same effect regardless of source. RESULTS: LOY was associated with increased EOC risk (OR per year increase = 1.014, 95% CI = 1.009 to 1.020 to OR per year increase = 1.044, 95% CI = 1.041 to 1.048). Individual LOY components, except age at menarche, also associated with EOC. The estimated model coefficient for oral contraceptive use and pregnancies were 4.45 times and 12- to 15-fold greater than expected, respectively. LOY was associated with high-grade serous, low-grade serous, endometrioid, and clear cell histotypes (ORs per year increase = 1.054, 1.040, 1.065, and 1.098, respectively) but not mucinous tumors. Estimated coefficients of LOY components were close to expected estimates for high-grade serous but larger than expected for low-grade serous, endometrioid, and clear cell histotypes. CONCLUSIONS: LOY is positively associated with nonmucinous EOC. Differences between estimated and expected model coefficients for LOY components suggest factors beyond ovulation underlie the associations between LOY components and EOC in general and for non-HGSOC.

Published
2023

22. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis

Author

Fu, Z, Brooks, MM, Irvin, S, Jordan, S, Aben, KKH, Anton-Culver, H, Bandera, E, Beckmann, MW, Berchuck, A, Brooks-Wilson, A, Chang-Claude, J, Cook, LS, Cramer, DW, Cushing-Haugen, KL, Doherty, JA, Ekici, AB, Fasching, PA, Fortner, RT, Gayther, SA, Gentry-Maharaj, A, Giles, GG, Goode, EL, Goodman, MT, Harris, HR, Hein, A, Kaaks, R, Kiemeney, LA, Koebel, M, Kotsopoulos, J, Le, ND, Lee, AW, Matsuo, K, McGuire, V, McLaughlin, JR, Menon, U, Milne, RL, Moysich, KB, Pearce, CL, Pike, MC, Qin, B, Ramus, SJ, Riggan, MJ, Rothstein, JH, Schildkraut, JM, Sieh, W, Sutphen, R, Terry, KL, Thompson, PJ, Titus, L, van Altena, AM, White, E, Whittemore, AS, Wu, AH, Zheng, W, Ziogas, A, Taylor, SE, Tang, L, Songer, T, Wentzensen, N, Webb, PM, Risch, HA, Modugno, F, Fu, Z, Brooks, MM, Irvin, S, Jordan, S, Aben, KKH, Anton-Culver, H, Bandera, E, Beckmann, MW, Berchuck, A, Brooks-Wilson, A, Chang-Claude, J, Cook, LS, Cramer, DW, Cushing-Haugen, KL, Doherty, JA, Ekici, AB, Fasching, PA, Fortner, RT, Gayther, SA, Gentry-Maharaj, A, Giles, GG, Goode, EL, Goodman, MT, Harris, HR, Hein, A, Kaaks, R, Kiemeney, LA, Koebel, M, Kotsopoulos, J, Le, ND, Lee, AW, Matsuo, K, McGuire, V, McLaughlin, JR, Menon, U, Milne, RL, Moysich, KB, Pearce, CL, Pike, MC, Qin, B, Ramus, SJ, Riggan, MJ, Rothstein, JH, Schildkraut, JM, Sieh, W, Sutphen, R, Terry, KL, Thompson, PJ, Titus, L, van Altena, AM, White, E, Whittemore, AS, Wu, AH, Zheng, W, Ziogas, A, Taylor, SE, Tang, L, Songer, T, Wentzensen, N, Webb, PM, Risch, HA, and Modugno, F

Abstract

BACKGROUND: The role of ovulation in epithelial ovarian cancer (EOC) is supported by the consistent protective effects of parity and oral contraceptive use. Whether these factors protect through anovulation alone remains unclear. We explored the association between lifetime ovulatory years (LOY) and EOC. METHODS: LOY was calculated using 12 algorithms. Odds ratios (ORs) and 95% confidence intervals (CIs) estimated the association between LOY or LOY components and EOC among 26 204 control participants and 21 267 case patients from 25 studies. To assess whether LOY components act through ovulation suppression alone, we compared beta coefficients obtained from regression models with expected estimates assuming 1 year of ovulation suppression has the same effect regardless of source. RESULTS: LOY was associated with increased EOC risk (OR per year increase = 1.014, 95% CI = 1.009 to 1.020 to OR per year increase = 1.044, 95% CI = 1.041 to 1.048). Individual LOY components, except age at menarche, also associated with EOC. The estimated model coefficient for oral contraceptive use and pregnancies were 4.45 times and 12- to 15-fold greater than expected, respectively. LOY was associated with high-grade serous, low-grade serous, endometrioid, and clear cell histotypes (ORs per year increase = 1.054, 1.040, 1.065, and 1.098, respectively) but not mucinous tumors. Estimated coefficients of LOY components were close to expected estimates for high-grade serous but larger than expected for low-grade serous, endometrioid, and clear cell histotypes. CONCLUSIONS: LOY is positively associated with nonmucinous EOC. Differences between estimated and expected model coefficients for LOY components suggest factors beyond ovulation underlie the associations between LOY components and EOC in general and for non-HGSOC.

Published
2023

23. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery

Author

Phung, MT, Webb, PM, DeFazio, A, Fereday, S, Lee, AW, Bowtell, DDL, Fasching, PA, Goode, EL, Goodman, MT, Karlan, BY, Lester, J, Matsuo, K, Modugno, F, Brenton, JD, Van Gorp, T, Pharoah, PDP, Schildkraut, JM, McLean, K, Meza, R, Mukherjee, B, Richardson, J, Grout, B, Chase, A, Deurloo, CM, Terry, KL, Hanley, GE, Pike, MC, Berchuck, A, Ramus, SJ, Pearce, CL, Ovarian, CAC, Phung, MT, Webb, PM, DeFazio, A, Fereday, S, Lee, AW, Bowtell, DDL, Fasching, PA, Goode, EL, Goodman, MT, Karlan, BY, Lester, J, Matsuo, K, Modugno, F, Brenton, JD, Van Gorp, T, Pharoah, PDP, Schildkraut, JM, McLean, K, Meza, R, Mukherjee, B, Richardson, J, Grout, B, Chase, A, Deurloo, CM, Terry, KL, Hanley, GE, Pike, MC, Berchuck, A, Ramus, SJ, Pearce, CL, and Ovarian, CAC

Abstract

OBJECTIVE: The presence of macroscopic residual disease after primary cytoreductive surgery (PCS) is an important factor influencing survival for patients with high-grade serous ovarian cancer (HGSC). More research is needed to identify factors associated with having macroscopic residual disease. We analyzed 12 lifestyle and personal exposures known to be related to ovarian cancer risk or inflammation to identify those associated with having residual disease after surgery. METHODS: This analysis used data on 2054 patients with advanced stage HGSC from the Ovarian Cancer Association Consortium. The exposures were body mass index, breastfeeding, oral contraceptive use, depot-medroxyprogesterone acetate use, endometriosis, first-degree family history of ovarian cancer, incomplete pregnancy, menopausal hormone therapy use, menopausal status, parity, smoking, and tubal ligation. Logistic regression models were fit to assess the association between these exposures and having residual disease following PCS. RESULTS: Menopausal estrogen-only therapy (ET) use was associated with 33% lower odds of having macroscopic residual disease compared to never use (OR = 0.67, 95%CI 0.46-0.97, p = 0.033). Compared to nulliparous women, parous women who did not breastfeed had 36% lower odds of having residual disease (OR = 0.64, 95%CI 0.43-0.94, p = 0.022), while there was no association among parous women who breastfed (OR = 0.90, 95%CI 0.65-1.25, p = 0.53). CONCLUSIONS: The association between ET and having no macroscopic residual disease is plausible given a strong underlying biologic hypothesis between this exposure and diagnosis with HGSC. If this or the parity finding is replicated, these factors could be included in risk stratification models to determine whether HGSC patients should receive PCS or neoadjuvant chemotherapy.

Published
2023

24. Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium

Author

Goyal, N., Hennessy, M., Lehman, E., Lin, W., Agudo, A., Ahrens, W., Boccia, Stefania, Brennan, P., Brenner, H., Cadoni, Gabriella, Canova, C., Chen, Chen, Conway, D., Curado, M., Dal Maso, L., Daudt, A. W., Edefonti, V., Fabianova, E., Fernandez, L., Franceschi, S., Garavello, W., Gillison, M., Hayes, R. B., Healy, C., Herrero, R., Holcatova, I., Kanda, J. L., Kelsey, K., Hansen, B., Koifman, R., Lagiou, Pagona, La Vecchia, C., Levi, F., Li, G., Lissowska, J., Mendoza Lopez, R., Luce, D., Macfarlane, G., Mates, D., Matsuo, K., Mcclean, M., Menezes, A., Menvielle, G., Morgenstern, H., Moysich, K., Negri, Erica, Olshan, A. F., Pandics, T., Polesel, J., Purdue, M., Radoi, L., Ramroth, H., Richiardi, L., Schantz, S., Schwartz, S. M., Serraino, D., Shangina, O., Smith, E., Sturgis, E. M., Swiatkowska, B., Thomson, P., Vaughan, T. L., Vilensky, M., Winn, D. M., Wunsch-Filho, V., Yu, G. -P., Zevallos, J. P., Zhang, Z. -F., Zheng, T., Znaor, A., Boffetta, Paolo, Hashibe, M., Lee, Y. -C. A., Muscat, J. E., Boccia S. (ORCID:0000-0002-1864-749X), Cadoni G. (ORCID:0000-0001-8244-784X), Chen C., Lagiou P., Negri E., Boffetta P., Goyal, N., Hennessy, M., Lehman, E., Lin, W., Agudo, A., Ahrens, W., Boccia, Stefania, Brennan, P., Brenner, H., Cadoni, Gabriella, Canova, C., Chen, Chen, Conway, D., Curado, M., Dal Maso, L., Daudt, A. W., Edefonti, V., Fabianova, E., Fernandez, L., Franceschi, S., Garavello, W., Gillison, M., Hayes, R. B., Healy, C., Herrero, R., Holcatova, I., Kanda, J. L., Kelsey, K., Hansen, B., Koifman, R., Lagiou, Pagona, La Vecchia, C., Levi, F., Li, G., Lissowska, J., Mendoza Lopez, R., Luce, D., Macfarlane, G., Mates, D., Matsuo, K., Mcclean, M., Menezes, A., Menvielle, G., Morgenstern, H., Moysich, K., Negri, Erica, Olshan, A. F., Pandics, T., Polesel, J., Purdue, M., Radoi, L., Ramroth, H., Richiardi, L., Schantz, S., Schwartz, S. M., Serraino, D., Shangina, O., Smith, E., Sturgis, E. M., Swiatkowska, B., Thomson, P., Vaughan, T. L., Vilensky, M., Winn, D. M., Wunsch-Filho, V., Yu, G. -P., Zevallos, J. P., Zhang, Z. -F., Zheng, T., Znaor, A., Boffetta, Paolo, Hashibe, M., Lee, Y. -C. A., Muscat, J. E., Boccia S. (ORCID:0000-0002-1864-749X), Cadoni G. (ORCID:0000-0001-8244-784X), Chen C., Lagiou P., Negri E., and Boffetta P.

Abstract

Objective We analyzed the pooled case-control data from the International Head and Neck Cancer Epidemiology (INHANCE) consortium to compare cigarette smoking and alcohol consumption risk factors for head and neck cancer between less developed and more developed countries. Subjects and Methods The location of each study was categorized as either a less developed or more developed country. We compared the risk of overall head and neck cancer and cancer of specific anatomic subsites associated with cigarette smoking and alcohol consumption. Additionally, age and sex distribution between categories was compared. Results The odds ratios for head and neck cancer sites associated with smoking duration differed between less developed and more developed countries. Smoking greater than 20 years conferred a higher risk for oral cavity and laryngeal cancer in more developed countries, whereas the risk was greater for oropharynx and hypopharynx cancer in less developed countries. Alcohol consumed for more than 20 years conferred a higher risk for oropharynx, hypopharynx, and larynx cancer in less developed countries. The proportion of cases that were young (<45 years) or female differed by country type for some HNC subsites. Conclusion These findings suggest the degree of industrialization and economic development affects the relationship between smoking and alcohol with head and neck cancer.

Published
2023

26. Geodetic measurements and quantitative evaluation for reduced gravitational redshift uncertainty of optical frequency standards

Author

Ichikawa, R., Hachisu, H., Sekido, M., Ido, T., Hiraoka, Y., Harima, E., Fukaya, S., Matsuo, K., Nakashima, M., Hattori, A., Aoyama, Y., Fukuda, Y., Imanishi, Y., Honda, R., and Kazama, T.

Abstract

The National Institute of Information and Communications Technology (NICT) has developed a Sr optical lattice clock and optical ion clocks employing In+and Ca+. The centimeter-level uncertainty of site elevation is the cause of 10^(-18)-level frequency uncertainties of optical frequency standards. It is significantly important to understand frequency changes caused by solid-earth tides that often range from 10 to 20 cm in amplitude, by oceanic tidal loading, crustal deformations due to earthquakes, and ground movements with groundwater changes for the stable operation of optical atomic clocks.NICT and partners including the Geospatial Information Authority of Japan (GSI) have been jointly conducting leveling surveys and relative gravimeter observations at NICT’s headquarters in Koganei. These observations reduce the contribution of gravitational redshift to the total uncertainty of the optical lattice clock to the 10^(-19)level. With the support of National Institute of Polar Research (NIPR), absolute gravity measurements were performed in August 2019 and May 2022 to evaluate the effects of the 2011 off the Pacific coast of Tohoku Earthquake on postseismic crustal movement. The obtained absolute gravity change between the two periods was -43.8 μGal, which matches the trend of GNSS vertical movement obtained by GSI. We have introduced a Micro-g LaCoste’s gPhoneX gravimeter for continuous gravity measurements nearby the optical clocks in the end of 2021 and have started to investigate the temporal variation of the ground water level in Koganei. We will present preliminary results of these geodetic measurements., The 28th IUGG General Assembly (IUGG2023) (Berlin 2023)

Published
2023
Full Text
View/download PDF

30. EP.06B.04 Aging Alteration of Biomarkers and Its Prognostic Role in Elderly Lung Cancer Patients Treated with Adjuvant S-1 Chemotherapy

Author

Soh, J., Yamamoto, H., Okumura, N., Suzuki, H., Nakata, M., Fujiwara, T., Genma, K., Sano, I., Fujinaga, T., Kataoka, M., Terazaki, Y., Fujimoto, N., Kataoka, K., Kosaka, S., Yamashita, M., Inokawa, H., Inoue, M., Nakamura, H., Yamashita, Y., Takahashi, Y., Torigoe, H., Sato, H., Tomida, S., Hotta, K., Yoshioka, H., Morita, S., Matsuo, K., Sakamoto, J., Date, H., and Toyooka, S.

Published
2024
Full Text
View/download PDF

34. Abstract No. 123 Impact of ablation margin on local tumor progression after radiofrequency ablation for lung metastases from colorectal carcinoma: supplementary analysis of phase II trial (MLCSG-0802)

Author

Hasegawa, T., primary, Takaki, H., additional, Kodama, H., additional, Matsuo, K., additional, Yamanaka, T., additional, Nakatsuka, A., additional, Inaba, Y., additional, Gobara, H., additional, Hayashi, S., additional, Takao, M., additional, and Yamakado, K., additional

Published
2022
Full Text
View/download PDF

35. OP0112 THE EVER-LARGEST ASIAN GWAS FOR SYSTEMIC SCLEROSIS AND TRANS-POPULATION META-ANALYSIS IDENTIFIED SEVEN NOVEL LOCI AND A CANDIDATE CAUSAL SNP IN A CIS-REGULATORY ELEMENT OF THE FCGR REGION

Author

Ishikawa, Y., primary, Tanaka, N., additional, Asano, Y., additional, Kodera, M., additional, Shirai, Y., additional, Akahoshi, M., additional, Hasegawa, M., additional, Matsushita, T., additional, Kazuyoshi, S., additional, Motegi, S., additional, Yoshifuji, H., additional, Yoshizaki, A., additional, Kohmoto, T., additional, Takagi, K., additional, Oka, A., additional, Kanda, M., additional, Tanaka, Y., additional, Ito, Y., additional, Nakano, K., additional, Kasamatsu, H., additional, Utsunomiya, A., additional, Sekiguchi, A., additional, Niro, H., additional, Jinnin, M., additional, Makino, K., additional, Makino, T., additional, Ihn, H., additional, Yamamoto, M., additional, Suzuki, C., additional, Takahashi, H., additional, Nishida, E., additional, Morita, A., additional, Yamamoto, T., additional, Fujimoto, M., additional, Kondo, Y., additional, Goto, D., additional, Sumida, T., additional, Ayuzawa, N., additional, Yanagida, H., additional, Horita, T., additional, Atsumi, T., additional, Endo, H., additional, Shima, Y., additional, Kumanogoh, A., additional, Hirata, J., additional, Otomo, N., additional, Suetsugu, H., additional, Koike, Y., additional, Tomizuka, K., additional, Yoshino, S., additional, Liu, X., additional, Ito, S., additional, Hikino, K., additional, Suzuki, A., additional, Momozawa, Y., additional, Ikegawa, S., additional, Ishikawa, O., additional, Takehara, K., additional, Torii, T., additional, Sato, S., additional, Okada, Y., additional, Mimori, T., additional, Matsuda, F., additional, Matsuda, K., additional, Imoto, I., additional, Matsuo, K., additional, Kuwana, M., additional, Kawaguchi, Y., additional, Ohmura, K., additional, and Terao, C., additional

Published
2022
Full Text
View/download PDF

36. High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival

Author

Brieger, KK, Phung, MT, Mukherjee, B, Bakulski, KM, Anton-Culver, H, Bandera, E, Bowtell, DDL, Cramer, DW, DeFazio, A, Doherty, JA, Fereday, S, Fortner, RT, Gentry-Maharaj, A, Goode, EL, Goodman, MT, Harris, HR, Matsuo, K, Menon, U, Modugno, F, Moysich, KB, Qin, B, Ramus, SJ, Risch, HA, Rossing, MA, Schildkraut, JM, Trabert, B, Vierkant, RA, Winham, SJ, Wentzensen, N, Wu, AH, Ziogas, A, Khoja, L, Cho, KR, McLean, K, Richardson, J, Grout, B, Chase, A, Deurloo, CM, Odunsi, K, Nelson, BH, Brenton, JD, Terry, KL, Pharoah, PDP, Berchuck, A, Hanley, GE, Webb, PM, Pike, MC, Pearce, CL, Brieger, KK, Phung, MT, Mukherjee, B, Bakulski, KM, Anton-Culver, H, Bandera, E, Bowtell, DDL, Cramer, DW, DeFazio, A, Doherty, JA, Fereday, S, Fortner, RT, Gentry-Maharaj, A, Goode, EL, Goodman, MT, Harris, HR, Matsuo, K, Menon, U, Modugno, F, Moysich, KB, Qin, B, Ramus, SJ, Risch, HA, Rossing, MA, Schildkraut, JM, Trabert, B, Vierkant, RA, Winham, SJ, Wentzensen, N, Wu, AH, Ziogas, A, Khoja, L, Cho, KR, McLean, K, Richardson, J, Grout, B, Chase, A, Deurloo, CM, Odunsi, K, Nelson, BH, Brenton, JD, Terry, KL, Pharoah, PDP, Berchuck, A, Hanley, GE, Webb, PM, Pike, MC, and Pearce, CL

Abstract

BACKGROUND: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed to identify inflammation-related factors that are associated with ovarian cancer survival and to determine their combined effects. METHODS: This analysis used pooled data on 8,147 women with invasive epithelial ovarian cancer from the Ovarian Cancer Association Consortium. The prediagnosis inflammation-related exposures of interest included alcohol use; aspirin use; other nonsteroidal anti-inflammatory drug use; body mass index; environmental tobacco smoke exposure; history of pelvic inflammatory disease, polycystic ovarian syndrome, and endometriosis; menopausal hormone therapy use; physical inactivity; smoking status; and talc use. Using Cox proportional hazards models, the relationship between each exposure and survival was assessed in 50% of the data. A weighted inflammation-related risk score (IRRS) was developed, and its association with survival was assessed using Cox proportional hazards models in the remaining 50% of the data. RESULTS: There was a statistically significant trend of increasing risk of death per quartile of the IRRS [HR = 1.09; 95% confidence interval (CI), 1.03-1.14]. Women in the upper quartile of the IRRS had a 31% higher death rate compared with the lowest quartile (95% CI, 1.11-1.54). CONCLUSIONS: A higher prediagnosis IRRS was associated with an increased mortality risk after an ovarian cancer diagnosis. Further investigation is warranted to evaluate whether postdiagnosis exposures are also associated with survival. IMPACT: Given that pre- and postdiagnosis exposures are often correlated and many are modifiable, our study results can ultimately motivate the development of behavioral recommendations to enhance survival among patients with ovarian cancer.

Published
2022

37. Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

Author

Dareng, EO, Tyrer, JP, Barnes, DR, Jones, MR, Yang, X, Aben, KKH, Adank, MA, Agata, S, Andrulis, IL, Anton-Culver, H, Antonenkova, NN, Aravantinos, G, Arun, BK, Augustinsson, A, Balmaña, J, Bandera, EV, Barkardottir, RB, Barrowdale, D, Beckmann, MW, Beeghly-Fadiel, A, Benitez, J, Bermisheva, M, Bernardini, MQ, Bjorge, L, Black, A, Bogdanova, NV, Bonanni, B, Borg, A, Brenton, JD, Budzilowska, A, Butzow, R, Buys, SS, Cai, H, Caligo, MA, Campbell, I, Cannioto, R, Cassingham, H, Chang-Claude, J, Chanock, SJ, Chen, K, Chiew, Y-E, Chung, WK, Claes, KBM, Colonna, S, GEMO Study Collaborators, GC-HBOC Study Collaborators, EMBRACE Collaborators, Cook, LS, Couch, FJ, Daly, MB, Dao, F, Davies, E, de la Hoya, M, de Putter, R, Dennis, J, DePersia, A, Devilee, P, Diez, O, Ding, YC, Doherty, JA, Domchek, SM, Dörk, T, du Bois, A, Dürst, M, Eccles, DM, Eliassen, HA, Engel, C, Evans, GD, Fasching, PA, Flanagan, JM, Fortner, RT, Machackova, E, Friedman, E, Ganz, PA, Garber, J, Gensini, F, Giles, GG, Glendon, G, Godwin, AK, Goodman, MT, Greene, MH, Gronwald, J, OPAL Study Group, AOCS Group, Hahnen, E, Haiman, CA, Håkansson, N, Hamann, U, Hansen, TVO, Harris, HR, Hartman, M, Heitz, F, Hildebrandt, MAT, Høgdall, E, Høgdall, CK, Hopper, JL, Huang, R-Y, Huff, C, Hulick, PJ, Huntsman, DG, Imyanitov, EN, KConFab Investigators, HEBON Investigators, Isaacs, C, Jakubowska, A, James, PA, Janavicius, R, Jensen, A, Johannsson, OT, John, EM, Jones, ME, Kang, D, Karlan, BY, Karnezis, A, Kelemen, LE, Khusnutdinova, E, Kiemeney, LA, Kim, B-G, Kjaer, SK, Komenaka, I, Kupryjanczyk, J, Kurian, AW, Kwong, A, Lambrechts, D, Larson, MC, Lazaro, C, Le, ND, Leslie, G, Lester, J, Lesueur, F, Levine, DA, Li, L, Li, J, Loud, JT, Lu, KH, Lubiński, J, Mai, PL, Manoukian, S, Marks, JR, Matsuno, RK, Matsuo, K, May, T, McGuffog, L, McLaughlin, JR, McNeish, IA, Mebirouk, N, Menon, U, Miller, A, Milne, RL, Minlikeeva, A, Modugno, F, Montagna, M, Moysich, KB, Munro, E, Nathanson, KL, Neuhausen, SL, Nevanlinna, H, Yie, JNY, Nielsen, HR, Nielsen, FC, Nikitina-Zake, L, Odunsi, K, Offit, K, Olah, E, Olbrecht, S, Olopade, OI, Olson, SH, Olsson, H, Osorio, A, Papi, L, Park, SK, Parsons, MT, Pathak, H, Pedersen, IS, Peixoto, A, Pejovic, T, Perez-Segura, P, Permuth, JB, Peshkin, B, Peterlongo, P, Piskorz, A, Prokofyeva, D, Radice, P, Rantala, J, Riggan, MJ, Risch, HA, Rodriguez-Antona, C, Ross, E, Rossing, MA, Runnebaum, I, Sandler, DP, Santamariña, M, Soucy, P, Schmutzler, RK, Setiawan, VW, Shan, K, Sieh, W, Simard, J, Singer, CF, Sokolenko, AP, Song, H, Southey, MC, Steed, H, Stoppa-Lyonnet, D, Sutphen, R, Swerdlow, AJ, Tan, YY, Teixeira, MR, Teo, SH, Terry, KL, Terry, MB, OCAC Consortium, CIMBA Consortium, Thomassen, M, Thompson, PJ, Thomsen, LCV, Thull, DL, Tischkowitz, M, Titus, L, Toland, AE, Torres, D, Trabert, B, Travis, R, Tung, N, Tworoger, SS, Valen, E, van Altena, AM, van der Hout, AH, Van Nieuwenhuysen, E, van Rensburg, EJ, Vega, A, Edwards, DV, Vierkant, RA, Wang, F, Wappenschmidt, B, Webb, PM, Weinberg, CR, Weitzel, JN, Wentzensen, N, White, E, Whittemore, AS, Winham, SJ, Wolk, A, Woo, Y-L, Wu, AH, Yan, L, Yannoukakos, D, Zavaglia, KM, Zheng, W, Ziogas, A, Zorn, KK, Kleibl, Z, Easton, D, Lawrenson, K, DeFazio, A, Sellers, TA, Ramus, SJ, Pearce, CL, Monteiro, AN, Cunningham, J, Goode, EL, Schildkraut, JM, Berchuck, A, Chenevix-Trench, G, Gayther, SA, Antoniou, AC, Pharoah, PDP, Dareng, EO, Tyrer, JP, Barnes, DR, Jones, MR, Yang, X, Aben, KKH, Adank, MA, Agata, S, Andrulis, IL, Anton-Culver, H, Antonenkova, NN, Aravantinos, G, Arun, BK, Augustinsson, A, Balmaña, J, Bandera, EV, Barkardottir, RB, Barrowdale, D, Beckmann, MW, Beeghly-Fadiel, A, Benitez, J, Bermisheva, M, Bernardini, MQ, Bjorge, L, Black, A, Bogdanova, NV, Bonanni, B, Borg, A, Brenton, JD, Budzilowska, A, Butzow, R, Buys, SS, Cai, H, Caligo, MA, Campbell, I, Cannioto, R, Cassingham, H, Chang-Claude, J, Chanock, SJ, Chen, K, Chiew, Y-E, Chung, WK, Claes, KBM, Colonna, S, GEMO Study Collaborators, GC-HBOC Study Collaborators, EMBRACE Collaborators, Cook, LS, Couch, FJ, Daly, MB, Dao, F, Davies, E, de la Hoya, M, de Putter, R, Dennis, J, DePersia, A, Devilee, P, Diez, O, Ding, YC, Doherty, JA, Domchek, SM, Dörk, T, du Bois, A, Dürst, M, Eccles, DM, Eliassen, HA, Engel, C, Evans, GD, Fasching, PA, Flanagan, JM, Fortner, RT, Machackova, E, Friedman, E, Ganz, PA, Garber, J, Gensini, F, Giles, GG, Glendon, G, Godwin, AK, Goodman, MT, Greene, MH, Gronwald, J, OPAL Study Group, AOCS Group, Hahnen, E, Haiman, CA, Håkansson, N, Hamann, U, Hansen, TVO, Harris, HR, Hartman, M, Heitz, F, Hildebrandt, MAT, Høgdall, E, Høgdall, CK, Hopper, JL, Huang, R-Y, Huff, C, Hulick, PJ, Huntsman, DG, Imyanitov, EN, KConFab Investigators, HEBON Investigators, Isaacs, C, Jakubowska, A, James, PA, Janavicius, R, Jensen, A, Johannsson, OT, John, EM, Jones, ME, Kang, D, Karlan, BY, Karnezis, A, Kelemen, LE, Khusnutdinova, E, Kiemeney, LA, Kim, B-G, Kjaer, SK, Komenaka, I, Kupryjanczyk, J, Kurian, AW, Kwong, A, Lambrechts, D, Larson, MC, Lazaro, C, Le, ND, Leslie, G, Lester, J, Lesueur, F, Levine, DA, Li, L, Li, J, Loud, JT, Lu, KH, Lubiński, J, Mai, PL, Manoukian, S, Marks, JR, Matsuno, RK, Matsuo, K, May, T, McGuffog, L, McLaughlin, JR, McNeish, IA, Mebirouk, N, Menon, U, Miller, A, Milne, RL, Minlikeeva, A, Modugno, F, Montagna, M, Moysich, KB, Munro, E, Nathanson, KL, Neuhausen, SL, Nevanlinna, H, Yie, JNY, Nielsen, HR, Nielsen, FC, Nikitina-Zake, L, Odunsi, K, Offit, K, Olah, E, Olbrecht, S, Olopade, OI, Olson, SH, Olsson, H, Osorio, A, Papi, L, Park, SK, Parsons, MT, Pathak, H, Pedersen, IS, Peixoto, A, Pejovic, T, Perez-Segura, P, Permuth, JB, Peshkin, B, Peterlongo, P, Piskorz, A, Prokofyeva, D, Radice, P, Rantala, J, Riggan, MJ, Risch, HA, Rodriguez-Antona, C, Ross, E, Rossing, MA, Runnebaum, I, Sandler, DP, Santamariña, M, Soucy, P, Schmutzler, RK, Setiawan, VW, Shan, K, Sieh, W, Simard, J, Singer, CF, Sokolenko, AP, Song, H, Southey, MC, Steed, H, Stoppa-Lyonnet, D, Sutphen, R, Swerdlow, AJ, Tan, YY, Teixeira, MR, Teo, SH, Terry, KL, Terry, MB, OCAC Consortium, CIMBA Consortium, Thomassen, M, Thompson, PJ, Thomsen, LCV, Thull, DL, Tischkowitz, M, Titus, L, Toland, AE, Torres, D, Trabert, B, Travis, R, Tung, N, Tworoger, SS, Valen, E, van Altena, AM, van der Hout, AH, Van Nieuwenhuysen, E, van Rensburg, EJ, Vega, A, Edwards, DV, Vierkant, RA, Wang, F, Wappenschmidt, B, Webb, PM, Weinberg, CR, Weitzel, JN, Wentzensen, N, White, E, Whittemore, AS, Winham, SJ, Wolk, A, Woo, Y-L, Wu, AH, Yan, L, Yannoukakos, D, Zavaglia, KM, Zheng, W, Ziogas, A, Zorn, KK, Kleibl, Z, Easton, D, Lawrenson, K, DeFazio, A, Sellers, TA, Ramus, SJ, Pearce, CL, Monteiro, AN, Cunningham, J, Goode, EL, Schildkraut, JM, Berchuck, A, Chenevix-Trench, G, Gayther, SA, Antoniou, AC, and Pharoah, PDP

Published
2022

38. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

Author

Dareng, EO, Tyrer, JP, Barnes, DR, Jones, MR, Yang, X, Aben, KKH, Adank, MA, Agata, S, Andrulis, IL, Anton-Culver, H, Antonenkova, NN, Aravantinos, G, Arun, BK, Augustinsson, A, Balmana, J, Bandera, E, Barkardottir, RB, Barrowdale, D, Beckmann, MW, Beeghly-Fadiel, A, Benitez, J, Bermisheva, M, Bernardini, MQ, Bjorge, L, Black, A, Bogdanova, N, Bonanni, B, Borg, A, Brenton, JD, Budzilowska, A, Butzow, R, Buys, SS, Cai, H, Caligo, MA, Campbell, I, Cannioto, R, Cassingham, H, Chang-Claude, J, Chanock, SJ, Chen, K, Chiew, Y-E, Chung, WK, Claes, KBM, Colonna, S, Cook, LS, Couch, FJ, Daly, MB, Dao, F, Davies, E, de la Hoya, M, de Putter, R, Dennis, J, DePersia, A, Devilee, P, Diez, O, Ding, YC, Doherty, JA, Domchek, SM, Dork, T, du Bois, A, Durst, M, Eccles, DM, Eliassen, HA, Engel, C, Evans, GD, Fasching, PA, Flanagan, JM, Fortner, R, Machackova, E, Friedman, E, Ganz, PA, Garber, J, Gensini, F, Giles, GG, Glendon, G, Godwin, AK, Goodman, MT, Greene, MH, Gronwald, J, Group, OS, AOCSGroup, Hahnen, E, Haiman, CA, Hakansson, N, Hamann, U, Hansen, TVO, Harris, HR, Hartman, M, Heitz, F, Hildebrandt, MAT, Hogdall, E, Hogdall, CK, Hopper, JL, Huang, R-Y, Huff, C, Hulick, PJ, Huntsman, DG, Imyanitov, EN, Isaacs, C, Jakubowska, A, James, PA, Janavicius, R, Jensen, A, Johannsson, OT, John, EM, Jones, ME, Kang, D, Karlan, BY, Karnezis, A, Kelemen, LE, Khusnutdinova, E, Kiemeney, LA, Kim, B-G, Kjaer, SK, Komenaka, I, Kupryjanczyk, J, Kurian, AW, Kwong, A, Lambrechts, D, Larson, MC, Lazaro, C, Le, ND, Leslie, G, Lester, J, Lesueur, F, Levine, DA, Li, L, Li, J, Loud, JT, Lu, KH, Mai, PL, Manoukian, S, Marks, JR, KimMatsuno, R, Matsuo, K, May, T, McGuffog, L, McLaughlin, JR, McNeish, IA, Mebirouk, N, Menon, U, Miller, A, Milne, RL, Minlikeeva, A, Modugno, F, Montagna, M, Moysich, KB, Munro, E, Nathanson, KL, Neuhausen, SL, Nevanlinna, H, Yie, JNY, Nielsen, HR, Nielsen, FC, Nikitina-Zake, L, Odunsi, K, Offit, K, Olah, E, Olbrecht, S, Olopade, O, Olson, SH, Olsson, H, Osorio, A, Papi, L, Park, SK, Parsons, MT, Pathak, H, Pedersen, IS, Peixoto, A, Pejovic, T, Perez-Segura, P, Permuth, JB, Peshkin, B, Peterlongo, P, Piskorz, A, Prokofyeva, D, Radice, P, Rantala, J, Riggan, MJ, Risch, HA, Rodriguez-Antona, C, Ross, E, Rossing, MA, Runnebaum, I, Sandler, DP, Santamarina, M, Soucy, P, Schmutzler, RK, Setiawan, VW, Shan, K, Sieh, W, Simard, J, Singer, CF, Sokolenko, AP, Song, H, Southey, MC, Steed, H, Stoppa-Lyonnet, D, Sutphen, R, Swerdlow, AJ, Tan, YY, Teixeira, MR, Teo, SH, Terry, KL, BethTerry, M, Thomassen, M, Thompson, PJ, Thomsen, LCV, Thull, DL, Tischkowitz, M, Titus, L, Toland, AE, Torres, D, Trabert, B, Travis, R, Tung, N, Tworoger, SS, Valen, E, van Altena, AM, van der Hout, AH, Nieuwenhuysen, E, van Rensburg, EJ, Vega, A, Edwards, DV, Vierkant, RA, Wang, F, Wappenschmidt, B, Webb, PM, Weinberg, CR, Weitzel, JN, Wentzensen, N, White, E, Whittemore, AS, Winham, SJ, Wolk, A, Woo, Y-L, Wu, AH, Yan, L, Yannoukakos, D, Zavaglia, KM, Zheng, W, Ziogas, A, Zorn, KK, Kleibl, Z, Easton, D, Lawrenson, K, DeFazio, A, Sellers, TA, Ramus, SJ, Pearce, CL, Monteiro, AN, Cunningham, J, Goode, EL, Schildkraut, JM, Berchuck, A, Chenevix-Trench, G, Gayther, SA, Antoniou, AC, Pharoah, PDP, Dareng, EO, Tyrer, JP, Barnes, DR, Jones, MR, Yang, X, Aben, KKH, Adank, MA, Agata, S, Andrulis, IL, Anton-Culver, H, Antonenkova, NN, Aravantinos, G, Arun, BK, Augustinsson, A, Balmana, J, Bandera, E, Barkardottir, RB, Barrowdale, D, Beckmann, MW, Beeghly-Fadiel, A, Benitez, J, Bermisheva, M, Bernardini, MQ, Bjorge, L, Black, A, Bogdanova, N, Bonanni, B, Borg, A, Brenton, JD, Budzilowska, A, Butzow, R, Buys, SS, Cai, H, Caligo, MA, Campbell, I, Cannioto, R, Cassingham, H, Chang-Claude, J, Chanock, SJ, Chen, K, Chiew, Y-E, Chung, WK, Claes, KBM, Colonna, S, Cook, LS, Couch, FJ, Daly, MB, Dao, F, Davies, E, de la Hoya, M, de Putter, R, Dennis, J, DePersia, A, Devilee, P, Diez, O, Ding, YC, Doherty, JA, Domchek, SM, Dork, T, du Bois, A, Durst, M, Eccles, DM, Eliassen, HA, Engel, C, Evans, GD, Fasching, PA, Flanagan, JM, Fortner, R, Machackova, E, Friedman, E, Ganz, PA, Garber, J, Gensini, F, Giles, GG, Glendon, G, Godwin, AK, Goodman, MT, Greene, MH, Gronwald, J, Group, OS, AOCSGroup, Hahnen, E, Haiman, CA, Hakansson, N, Hamann, U, Hansen, TVO, Harris, HR, Hartman, M, Heitz, F, Hildebrandt, MAT, Hogdall, E, Hogdall, CK, Hopper, JL, Huang, R-Y, Huff, C, Hulick, PJ, Huntsman, DG, Imyanitov, EN, Isaacs, C, Jakubowska, A, James, PA, Janavicius, R, Jensen, A, Johannsson, OT, John, EM, Jones, ME, Kang, D, Karlan, BY, Karnezis, A, Kelemen, LE, Khusnutdinova, E, Kiemeney, LA, Kim, B-G, Kjaer, SK, Komenaka, I, Kupryjanczyk, J, Kurian, AW, Kwong, A, Lambrechts, D, Larson, MC, Lazaro, C, Le, ND, Leslie, G, Lester, J, Lesueur, F, Levine, DA, Li, L, Li, J, Loud, JT, Lu, KH, Mai, PL, Manoukian, S, Marks, JR, KimMatsuno, R, Matsuo, K, May, T, McGuffog, L, McLaughlin, JR, McNeish, IA, Mebirouk, N, Menon, U, Miller, A, Milne, RL, Minlikeeva, A, Modugno, F, Montagna, M, Moysich, KB, Munro, E, Nathanson, KL, Neuhausen, SL, Nevanlinna, H, Yie, JNY, Nielsen, HR, Nielsen, FC, Nikitina-Zake, L, Odunsi, K, Offit, K, Olah, E, Olbrecht, S, Olopade, O, Olson, SH, Olsson, H, Osorio, A, Papi, L, Park, SK, Parsons, MT, Pathak, H, Pedersen, IS, Peixoto, A, Pejovic, T, Perez-Segura, P, Permuth, JB, Peshkin, B, Peterlongo, P, Piskorz, A, Prokofyeva, D, Radice, P, Rantala, J, Riggan, MJ, Risch, HA, Rodriguez-Antona, C, Ross, E, Rossing, MA, Runnebaum, I, Sandler, DP, Santamarina, M, Soucy, P, Schmutzler, RK, Setiawan, VW, Shan, K, Sieh, W, Simard, J, Singer, CF, Sokolenko, AP, Song, H, Southey, MC, Steed, H, Stoppa-Lyonnet, D, Sutphen, R, Swerdlow, AJ, Tan, YY, Teixeira, MR, Teo, SH, Terry, KL, BethTerry, M, Thomassen, M, Thompson, PJ, Thomsen, LCV, Thull, DL, Tischkowitz, M, Titus, L, Toland, AE, Torres, D, Trabert, B, Travis, R, Tung, N, Tworoger, SS, Valen, E, van Altena, AM, van der Hout, AH, Nieuwenhuysen, E, van Rensburg, EJ, Vega, A, Edwards, DV, Vierkant, RA, Wang, F, Wappenschmidt, B, Webb, PM, Weinberg, CR, Weitzel, JN, Wentzensen, N, White, E, Whittemore, AS, Winham, SJ, Wolk, A, Woo, Y-L, Wu, AH, Yan, L, Yannoukakos, D, Zavaglia, KM, Zheng, W, Ziogas, A, Zorn, KK, Kleibl, Z, Easton, D, Lawrenson, K, DeFazio, A, Sellers, TA, Ramus, SJ, Pearce, CL, Monteiro, AN, Cunningham, J, Goode, EL, Schildkraut, JM, Berchuck, A, Chenevix-Trench, G, Gayther, SA, Antoniou, AC, and Pharoah, PDP

Abstract

Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, "select and shrink for summary statistics" (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28-1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08-1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21-1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29-1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35-1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.

Published
2022

39. Incorporating progesterone receptor expression into the PREDICT breast prognostic model

Author

Grootes, I, Keeman, R, Blows, FM, Milne, RL, Giles, GG, Swerdlow, AJ, Fasching, PA, Abubakar, M, Andrulis, IL, Anton-Culver, H, Beckmann, MW, Blomqvist, C, Bojesen, SE, Bolla, MK, Bonanni, B, Briceno, I, Burwinkel, B, Camp, NJ, Castelao, JE, Choi, J-Y, Clarke, CL, Couch, FJ, Cox, A, Cross, SS, Czene, K, Devilee, P, Dork, T, Dunning, AM, Dwek, M, Easton, DF, Eccles, DM, Eriksson, M, Ernst, K, Evans, DG, Figueroa, JD, Fink, V, Floris, G, Fox, S, Gabrielson, M, Gago-Dominguez, M, Garcia-Saenz, JA, Gonzalez-Neira, A, Haeberle, L, Haiman, CA, Hall, P, Hamann, U, Harkness, EF, Hartman, M, Hein, A, Hooning, MJ, Hou, M-F, Howell, SJ, Ito, H, Jakubowska, A, Janni, W, John, EM, Jung, A, Kang, D, Kristensen, VN, Kwong, A, Lambrechts, D, Li, J, Manoochehri, M, Margolin, S, Matsuo, K, Taib, NAM, Mulligan, AM, Nevanlinna, H, Newman, WG, Offit, K, Osorio, A, Park, SK, Park-Simon, T-W, Patel, A, Presneau, N, Pylkas, K, Rack, B, Radice, P, Rennert, G, Romero, A, Saloustros, E, Sawyer, EJ, Schneeweiss, A, Schochter, F, Schoemaker, MJ, Shen, C-Y, Shibli, R, Sinn, P, Tapper, WJ, Tawfiq, E, Teo, SH, Teras, LR, Torres, D, Vachon, CM, van Deurzen, CHM, Wendt, C, Williams, JA, Winqvist, R, Elwood, M, Schmidt, MK, Pharoah, PDP, Grootes, I, Keeman, R, Blows, FM, Milne, RL, Giles, GG, Swerdlow, AJ, Fasching, PA, Abubakar, M, Andrulis, IL, Anton-Culver, H, Beckmann, MW, Blomqvist, C, Bojesen, SE, Bolla, MK, Bonanni, B, Briceno, I, Burwinkel, B, Camp, NJ, Castelao, JE, Choi, J-Y, Clarke, CL, Couch, FJ, Cox, A, Cross, SS, Czene, K, Devilee, P, Dork, T, Dunning, AM, Dwek, M, Easton, DF, Eccles, DM, Eriksson, M, Ernst, K, Evans, DG, Figueroa, JD, Fink, V, Floris, G, Fox, S, Gabrielson, M, Gago-Dominguez, M, Garcia-Saenz, JA, Gonzalez-Neira, A, Haeberle, L, Haiman, CA, Hall, P, Hamann, U, Harkness, EF, Hartman, M, Hein, A, Hooning, MJ, Hou, M-F, Howell, SJ, Ito, H, Jakubowska, A, Janni, W, John, EM, Jung, A, Kang, D, Kristensen, VN, Kwong, A, Lambrechts, D, Li, J, Manoochehri, M, Margolin, S, Matsuo, K, Taib, NAM, Mulligan, AM, Nevanlinna, H, Newman, WG, Offit, K, Osorio, A, Park, SK, Park-Simon, T-W, Patel, A, Presneau, N, Pylkas, K, Rack, B, Radice, P, Rennert, G, Romero, A, Saloustros, E, Sawyer, EJ, Schneeweiss, A, Schochter, F, Schoemaker, MJ, Shen, C-Y, Shibli, R, Sinn, P, Tapper, WJ, Tawfiq, E, Teo, SH, Teras, LR, Torres, D, Vachon, CM, van Deurzen, CHM, Wendt, C, Williams, JA, Winqvist, R, Elwood, M, Schmidt, MK, and Pharoah, PDP

Abstract

BACKGROUND: Predict Breast (www.predict.nhs.uk) is an online prognostication and treatment benefit tool for early invasive breast cancer. The aim of this study was to incorporate the prognostic effect of progesterone receptor (PR) status into a new version of PREDICT and to compare its performance to the current version (2.2). METHOD: The prognostic effect of PR status was based on the analysis of data from 45,088 European patients with breast cancer from 49 studies in the Breast Cancer Association Consortium. Cox proportional hazard models were used to estimate the hazard ratio for PR status. Data from a New Zealand study of 11,365 patients with early invasive breast cancer were used for external validation. Model calibration and discrimination were used to test the model performance. RESULTS: Having a PR-positive tumour was associated with a 23% and 28% lower risk of dying from breast cancer for women with oestrogen receptor (ER)-negative and ER-positive breast cancer, respectively. The area under the ROC curve increased with the addition of PR status from 0.807 to 0.809 for patients with ER-negative tumours (p = 0.023) and from 0.898 to 0.902 for patients with ER-positive tumours (p = 2.3 × 10-6) in the New Zealand cohort. Model calibration was modest with 940 observed deaths compared to 1151 predicted. CONCLUSION: The inclusion of the prognostic effect of PR status to PREDICT Breast has led to an improvement of model performance and more accurate absolute treatment benefit predictions for individual patients. Further studies should determine whether the baseline hazard function requires recalibration.

Published
2022

42. Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium

Author

Goyal, N. Hennessy, M. Lehman, E. Lin, W. Agudo, A. Ahrens, W. Boccia, S. Brennan, P. Brenner, H. Cadoni, G. Canova, C. Chen, C. Conway, D. Curado, M. Dal Maso, L. Daudt, A.W. Edefonti, V. Fabianova, E. Fernandez, L. Franceschi, S. Garavello, W. Gillison, M. Hayes, R.B. Healy, C. Herrero, R. Holcatova, I. Kanda, J.L. Kelsey, K. Hansen, B. Koifman, R. Lagiou, P. La Vecchia, C. Levi, F. Li, G. Lissowska, J. Mendoza López, R. Luce, D. Macfarlane, G. Mates, D. Matsuo, K. McClean, M. Menezes, A. Menvielle, G. Morgenstern, H. Moysich, K. Negri, E. Olshan, A.F. Pandics, T. Polesel, J. Purdue, M. Radoi, L. Ramroth, H. Richiardi, L. Schantz, S. Schwartz, S.M. Serraino, D. Shangina, O. Smith, E. Sturgis, E.M. Świątkowska, B. Thomson, P. Vaughan, T.L. Vilensky, M. Winn, D.M. Wunsch-Filho, V. Yu, G.-P. Zevallos, J.P. Zhang, Z.-F. Zheng, T. Znaor, A. Boffetta, P. Hashibe, M. Lee, Y.-C.A. Muscat, J.E.

Abstract

Objective: We analyzed the pooled case-control data from the International Head and Neck Cancer Epidemiology (INHANCE) consortium to compare cigarette smoking and alcohol consumption risk factors for head and neck cancer between less developed and more developed countries. Subjects and Methods: The location of each study was categorized as either a less developed or more developed country. We compared the risk of overall head and neck cancer and cancer of specific anatomic subsites associated with cigarette smoking and alcohol consumption. Additionally, age and sex distribution between categories was compared. Results: The odds ratios for head and neck cancer sites associated with smoking duration differed between less developed and more developed countries. Smoking greater than 20 years conferred a higher risk for oral cavity and laryngeal cancer in more developed countries, whereas the risk was greater for oropharynx and hypopharynx cancer in less developed countries. Alcohol consumed for more than 20 years conferred a higher risk for oropharynx, hypopharynx, and larynx cancer in less developed countries. The proportion of cases that were young (

Published
2022

47. EPV033a/#697 Significance of histology and nodal status on the survival of women with early-stage cervical cancer: validation of the 2018 FIGO cervical cancer staging system

Author

Machida, H, primary, Matsuo, K, additional, Kobayashi, Y, additional, Momomura, M, additional, Takahashi, F, additional, Tabata, T, additional, Kondo, E, additional, Yamagami, W, additional, Ebina, Y, additional, Kaneuchi, M, additional, Nagase, S, additional, and Mikami, M, additional

Published
2021
Full Text
View/download PDF

49. EP09.91: Stratification of fetal therapy indication for the fetus with severe tricuspid valve dysplasia.

Author

Ishii, Y., Nagano, H., Hayashida, Y., Fujisaki, T., Mori, M., Matsuo, K., Asada, D., Kanaya, T., Tsumura, S., and Aoki, H.

Subjects
FETAL ultrasonic imaging, MATERNAL age, EBSTEIN'S anomaly, TRICUSPID valve, CONGENITAL heart disease
Abstract

This article discusses the severity and clinical course of tricuspid valve dysplasia (TVD) in fetuses and explores suitable cases for fetal treatment. The study presents the SAS score and TRIPP score for 20 TVD cases from 2013 to 2023. The results show that a SAS score and TRIPP score of 6 or higher indicate a higher risk of intrauterine fetal death (IUFD) and may be suitable for fetal treatment. The article concludes that stratifying severity using these scores is valuable in determining the need for fetal treatment. [Extracted from the article]

Published
2024
Full Text
View/download PDF

50. EP09.33: Utility of novel echocardiographic measurements to improve prenatal diagnosis of coarctation of the aorta.

Author

Fujisaki, T., Ishii, Y., Takahashi, K., Mori, M., Matsuo, K., Asada, D., Kanaya, T., Tsumura, S., Kayatani, F., and Aoki, H.

Subjects
RECEIVER operating characteristic curves, SUBCLAVIAN artery, THORACIC aorta, DUCTUS arteriosus, CAROTID artery, AORTIC coarctation
Abstract

This article, published in the journal Ultrasound in Obstetrics & Gynecology, discusses the challenges of prenatal diagnosis of coarctation of the aorta (CoA) and aims to identify a novel formula based on fetal echocardiographic measures to improve prenatal identification of CoA. The study compared echocardiographic evaluations of 30 patients with suspected CoA and found that measurements of aortic isthmus diameter, ductus arteriosus diameter/aortic isthmus diameter, and distal aortic arch (DA) index showed significant differences between the groups. The DA index was found to be the most effective measurement, with a cutoff value of 1.28 indicating cases requiring surgical intervention. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results